Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR. Nussenblatt RB, et al. Among authors: suhler eb. J Autoimmun. 2003 Nov;21(3):283-93. doi: 10.1016/s0896-8411(03)00113-6. J Autoimmun. 2003. PMID: 14599854 Clinical Trial.
Presumed teratoma-associated paraneoplastic retinopathy.
Suhler EB, Chan CC, Caruso RC, Schrump DS, Thirkill C, Smith JA, Nussenblatt RB, Buggage RR. Suhler EB, et al. Arch Ophthalmol. 2003 Jan;121(1):133-7. doi: 10.1001/archopht.121.1.133. Arch Ophthalmol. 2003. PMID: 12523906 No abstract available.
Mycophenolate mofetil for the treatment of scleritis.
Sen HN, Suhler EB, Al-Khatib SQ, Djalilian AR, Nussenblatt RB, Buggage RR. Sen HN, et al. Among authors: suhler eb. Ophthalmology. 2003 Sep;110(9):1750-5. doi: 10.1016/S0161-6420(03)00570-0. Ophthalmology. 2003. PMID: 13129873 Clinical Trial.
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ. Buggage RR, et al. Among authors: suhler eb. Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):63-70. doi: 10.1080/09273940701299370. Ocul Immunol Inflamm. 2007. PMID: 17558830 Free PMC article. Clinical Trial.
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.
Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kaçmaz RO, Pujari SS, Anzaar F, Foster CS, Helzlsouer KJ, Levy-Clarke GA, Nussenblatt RB, Liesegang T, Rosenbaum JT, Suhler EB. Kempen JH, et al. Among authors: suhler eb. Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):47-55. doi: 10.1080/09286580701585892. Ophthalmic Epidemiol. 2008. PMID: 18300089
133 results